Ramy Sedhom, MD, FASCO

Imagine 4 new anticancer drugs Pallituzumab, Geriatriximab, Symptomab, & Exercizumab hit the market. They should dominate the plenary sessions at ASCO & command billion-dollar revenue. But they don't because they're nonpharmacologic & shame on us. Read our opinion piece in @JCO_ASCO ascopubs.org/doi/full/10.12…

Our work showing an association between low income and caregiver loneliness. Important for those trying to develop clinical practices or infrastructure to ameliorate loneliness in caregivers of patients with cancer link.springer.com/article/10.100…

Nice perspective on spiritual well-being, patient experience and cancer care ascopubs.org/doi/full/10.12…

Can a default-assigned embedded EHR assessment be implemented in community oncology, and identify the aging-related needs of older adults? LDI Fellow @ramsedhom found that it can. A new @JCOOP_ASCO publication details implementation, and early outcomes: ascopubs.org/doi/10.1200/OP…

OS from the SONIA trial published in @JAMAOnc. A delayed use of CDK4/6-inhibitors (2L vs 1L) reduced toxicities and did not seem to compromise OS, although pre-menopausal patients did seem to benefit from an earlier use. Great editorial by @ValenzaCarmine jamanetwork.com/journals/jamao…

A brave and thoughtful paper. I couldn’t agree more

A new @PennMedicine program led by PC3I Faculty @ramsedhom, MD & Rebecca Boswell, PhD highlights how integrating mental health support into cancer care through a Psychosocial Oncology Clinic can help ease cancer’s emotional toll for patients & caregivers. pennmedicine.org/news/cancer-ca…

In recognition of World Cancer Day 🌐 we connected with @Ron_cology, @ramsedhom, @ScienceChow, and @andrewlipskymd to discuss lessons that have shaped their practice and the work they’re prioritizing next to move cancer care forward #WorldCancerDay #oncology Watch their insights here 🧬🗣️

Real-World Analysis Supports Rethinking Upfront Dose Intensity of Enfortumab Vedotin in Advanced Urothelial Cancer @ScienceChow @PennCancer @Ron_cology @ramsedhom #blcsm hubs.ly/Q041HfMF0

Practicing what we preach - incredibly proud of our psychosocial oncology service & our ability to treat the whole person pennmedicine.org/news/cancer-ca… “When patients confront cancer, the greatest wounds are not always physical”

Nvidia CEO Jensen Huang, with an incredibly thoughtful answer to the smartest person he's ever met. If you listen closely to the words he uses, including "empathy" and "wisdom," you'll realize a certain group of people he's not describing.

@PGrivasMDPhD @chadinabhan @LeonidasPlatan1 @BrainTumorDoc @VivekSubbiah @VenurVyshak @BradMcG04 @neerajaiims @BalazsHalmosMD @DrChoueiri @jrgralow @NazliDizman @OncoAlert Sorry brother Turkish style is best

I love @chadinabhan but he still can’t accept that Greek baklava is the clear winner as master @LeonidasPlatan1 said! This contest took place in Miami @BrainTumorDoc @VivekSubbiah @VenurVyshak @BradMcG04 @neerajaiims @BalazsHalmosMD @DrChoueiri @jrgralow @NazliDizman @OncoAlert

This changes practice. In a real-world study of T-DXd, early triple antiemetic prophylaxis cut dose reductions by ~50% (31% vs 67%). Supportive care works best when it starts early. tandfonline.com/doi/10.1080/14… @OncoAlert

@montypal @ASCO @jackiebrown_MD @AUC3_Official @DrChoueiri @DrRanaMcKay @OncoAlert Jackie is an awesome communicator and human being! Glad she is getting the spotlight

As with her stellar @ASCO talk, @jackiebrown_MD delivered a clear, concise and thoughtful talk about the post-EV landscape at @AUC3_Official - bravo! @DrChoueiri @DrRanaMcKay @OncoAlert

Embedding Geriatric Oncology in a Community Practice of an Academic Health System: Implementation, Outcomes, and End-of-Life Impact. Co-authored by @ramsedhom. Read the full article. brnw.ch/21wZkAH

I appreciate any criticism of supportive care - as it should be held to the same standard as a treatment trial. Is OS the endpoint that matters for palliative care? How about the quality of life, communication, and psychosocial outcomes from over 30 RCTs? And similarly for PROs & GA - there are patient centered outcomes that matter

Exercise trial has major issues. Early palliative care relies on underpowered second look at OS. The evidence for these is worse than traztuzumab or imatinib.

A Ph IV prospective study of efficacy&safety of ribociclib+letrozole as 1L therapy in older women (≥70 years) with HR+ HER2- advanced BC: the RibOB study in @ESMO_Open. Effective therapy in elderlies, frequent dose reductions/early discontinuations. esmoopen.com/article/S2059-…

Do we always need full dose ADCs to achieve benefit? In a 🇺🇸retrospective RWE cohort of previously treated mBC, starting T-DXd (n=66) or SG (n=48) at reduced dose was associated with similar PFS, OS & ORR vs standard dosing Not practice changing, but a clinically meaningful signal that merits further study. Well done work on a practical clinical question doi.org/10.1007/s10549… @OncoAlert

“Hard work doesn't always lead to success. Good systems do.” A thought-provoking piece! #pallonc #gerionc #PROMs #supponc

What a fantastic piece. Unless we improve health systems, these #groundshot type interventions can’t improve patient outcomes. It’s hypocritical that the system can easily pay 20K per patient per month on a brand new drug but can’t invest on health systems to deliver better and meaningful care.

When the System Is the Treatment: Rethinking Nonpharmacologic Breakthroughs in Oncology ascopubs.org/doi/10.1200/JC… via @ramsedhom et al @Maherjane @DrMarkLythgoe